Immutep S.a.s.
Clinical trials sponsored by Immutep S.a.s., explained in plain language.
-
Two-Drug immune attack shows promise against tough cancers
Disease control CompletedThis study tested a combination of two immunotherapy drugs (eftilagimod alpha and pembrolizumab) in 187 adults with advanced non-small cell lung cancer or head and neck cancer that had not responded to prior treatment. The goal was to see if the combo could shrink tumors safely. …
Phase: PHASE2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
New drug combo shows promise against hard-to-treat head and neck cancer
Disease control CompletedThis study tested whether adding an experimental drug (eftilagimod alpha) to a standard immunotherapy (pembrolizumab) works better than the standard drug alone for people with advanced head and neck cancer that cannot be removed by surgery. About 171 adults with PD-L1 positive or…
Phase: PHASE2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC